Nothing Special   »   [go: up one dir, main page]

ATE507295T1 - COMPOSITIONS AND METHODS FOR DENDRITIC CELL-BASED IMMUNOTHERAPY - Google Patents

COMPOSITIONS AND METHODS FOR DENDRITIC CELL-BASED IMMUNOTHERAPY

Info

Publication number
ATE507295T1
ATE507295T1 AT01920913T AT01920913T ATE507295T1 AT E507295 T1 ATE507295 T1 AT E507295T1 AT 01920913 T AT01920913 T AT 01920913T AT 01920913 T AT01920913 T AT 01920913T AT E507295 T1 ATE507295 T1 AT E507295T1
Authority
AT
Austria
Prior art keywords
compositions
methods
immunostimulatory
dendritic cell
based immunotherapy
Prior art date
Application number
AT01920913T
Other languages
German (de)
Inventor
Reiner Laus
Damir Vidovic
Thomas Graddis
Original Assignee
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendreon Corp filed Critical Dendreon Corp
Application granted granted Critical
Publication of ATE507295T1 publication Critical patent/ATE507295T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses in vitro and in vivo. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component derived from the intracellular domain of the HER-2 protein. Also disclosed are immunostimulatory compositions comprising dendritic cells pulsed with such an immunostimulatory fusion protein and methods for immunotherapy using the compositions.
AT01920913T 2000-03-30 2001-03-30 COMPOSITIONS AND METHODS FOR DENDRITIC CELL-BASED IMMUNOTHERAPY ATE507295T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19350400P 2000-03-30 2000-03-30
PCT/US2001/010515 WO2001074855A2 (en) 2000-03-30 2001-03-30 Compositions and methods for dendritic cell-based immunotherapy

Publications (1)

Publication Number Publication Date
ATE507295T1 true ATE507295T1 (en) 2011-05-15

Family

ID=22713907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01920913T ATE507295T1 (en) 2000-03-30 2001-03-30 COMPOSITIONS AND METHODS FOR DENDRITIC CELL-BASED IMMUNOTHERAPY

Country Status (13)

Country Link
US (2) US7060279B2 (en)
EP (1) EP1272633B1 (en)
JP (1) JP5110674B2 (en)
AT (1) ATE507295T1 (en)
AU (2) AU4791901A (en)
CA (1) CA2403964C (en)
CY (1) CY1111718T1 (en)
DE (1) DE60144516D1 (en)
DK (1) DK1272633T3 (en)
ES (1) ES2362715T3 (en)
NZ (1) NZ522066A (en)
PT (1) PT1272633E (en)
WO (1) WO2001074855A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
US7413869B2 (en) * 2002-04-05 2008-08-19 Dendreon Corporation Method for determining potency of antigenic presenting cell based vaccines
WO2003087338A2 (en) * 2002-04-11 2003-10-23 Amgen, Inc. Her-2 receptor tyrosine kinase molecules and uses thereof
ES2527946T3 (en) 2003-03-05 2015-02-02 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious diseases
WO2007147165A2 (en) * 2006-06-16 2007-12-21 Bresagen, Inc. Human cancer stem cell culture compositions comprising erbb2 variants and methods of use thereof
US7972602B2 (en) * 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2118128E (en) * 2007-01-15 2013-01-29 Glaxosmithkline Biolog Sa Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
US8309096B2 (en) 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
EP2118128B1 (en) * 2007-01-15 2012-11-07 GlaxoSmithKline Biologicals SA Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
US8153120B2 (en) * 2007-03-22 2012-04-10 Dendreon Corporation Methods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity
EP2780363B1 (en) 2011-11-17 2019-07-03 Glia SP Z.O.O. Compositions and methods for treating glioma
EP2777711A1 (en) * 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
WO2017096247A1 (en) 2015-12-04 2017-06-08 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different mhc molecules
TW202216776A (en) 2020-07-07 2022-05-01 美商康愈有限責任公司 Mic antibodies and binding agents and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2048981B (en) * 1979-05-23 1982-11-17 Coal Ind Equipment for laying a layer of elongate material adjacent to an exposed rock or mineral surface in an underground mine
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
CA2158281A1 (en) * 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5586538A (en) * 1995-11-13 1996-12-24 Caterpillar Inc. Method of correcting engine maps based on engine temperature
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
WO1998046769A1 (en) * 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
US6194152B1 (en) * 1997-08-20 2001-02-27 Dendreon Corporation Prostate tumor polynucleotide compositions and methods of detection thereof
NZ512807A (en) * 1998-12-14 2003-10-31 Dendreon Corp Compositions and methods for enhancement of major histocompatibility complex class 1 restricted antigen presentation by attaching the antigen to a specific peptide
CZ20012587A3 (en) * 1999-01-29 2002-05-15 Corixa Corporation Isolated protein, nucleic acid, virus vector, pharmaceutical preparation, isolated population of T cells, method of reinforcing immune response, method of removing tumor cells, method of stimulating and/or propagating T cells and process for preparing a fusion protein
IL145982A0 (en) * 1999-04-19 2002-07-25 Smithkline Beecham Biolog Vaccines
US6406681B1 (en) * 2000-08-21 2002-06-18 Aeropharm Technology, Inc. Method of treating a systemic disease

Also Published As

Publication number Publication date
EP1272633A2 (en) 2003-01-08
DK1272633T3 (en) 2011-05-23
US20050232932A1 (en) 2005-10-20
AU4791901A (en) 2001-10-15
WO2001074855A3 (en) 2002-03-07
EP1272633B1 (en) 2011-04-27
ES2362715T3 (en) 2011-07-12
NZ522066A (en) 2004-08-27
WO2001074855A2 (en) 2001-10-11
US7659117B2 (en) 2010-02-09
JP5110674B2 (en) 2012-12-26
CA2403964A1 (en) 2001-10-11
AU2001247919B2 (en) 2006-02-09
CA2403964C (en) 2013-04-30
CY1111718T1 (en) 2015-10-07
DE60144516D1 (en) 2011-06-09
US20020061310A1 (en) 2002-05-23
US7060279B2 (en) 2006-06-13
PT1272633E (en) 2011-06-27
JP2003529608A (en) 2003-10-07

Similar Documents

Publication Publication Date Title
ATE507295T1 (en) COMPOSITIONS AND METHODS FOR DENDRITIC CELL-BASED IMMUNOTHERAPY
DK0870022T3 (en) Immunostimulatory composition and method
Botarelli et al. N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes.
HK1058367A1 (en) Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of thes proteins
ATE437228T1 (en) DENDRITE CELL-SPECIFIC CO-STIMULATING MOLECULES
WO2001029233A3 (en) Chimeric immunogenic compositions and nucleic acids encoding them
CY1109649T1 (en) ANTIGENS AND COMPOSITIONS FROM NEISSERIA
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
HK1022715A1 (en) Fusion proteins containing stress proteins for inducing immune responses
CY1106842T1 (en) RECOMBINANT NODAVIRUS COMPOSITIONS AND METHODS
CY1109710T1 (en) Lymphocyte Auxiliary Site
DK1530637T3 (en) Carlsberg subtilisin proteins with reduced immunogenicity
MX2021011330A (en) Claudin-6 antibodies and drug conjugates.
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
WO2001087978A3 (en) Human abc transporter and its use
WO2004026238A3 (en) Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers
ATE389397T1 (en) ADJUVANT COMPOSITIONS
WO2001094949A3 (en) Soluble cd1 compositions and uses thereof
PT996636E (en) ANTIGENIC HA-1
AU3823601A (en) Cytotoxic t lymphocytes activated by dendritic cell hybrids
DE69426303D1 (en) METHOD FOR SUPPRESSING THE IMMUNE RESPONSE BY GENTHERAPY
WO2004020592A3 (en) Retroductal salivary gland genetic vaccination
DE60136832D1 (en) ATCR-1, A HUMAN ACYLTRANSFERASE AND USES THEREOF
TW200407334A (en) Trehalose receptor and method of detecting trehalose using the same
Gumperz Human CD1d-Restricted Natural Killer T (NKT) Cell Cytotoxicity Against Myeloid Cells

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272633

Country of ref document: EP